These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36174193)

  • 1. Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease.
    Rentsch CA; Ward MG; Luber RP; Taylor KM; Gibson DJ; Headon B; Rosella O; Su HY; Friedman AB; Dooley M; Sparrow MP; Gibson PR
    Ther Drug Monit; 2023 Jun; 45(3):383-391. PubMed ID: 36174193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA.
    Lim MH; Aluzaite K; Schultz M; Casey P
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1302-1306. PubMed ID: 31881552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
    J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
    Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
    Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
    Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
    Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
    PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
    Valdés-Delgado T; Aguado-Paredes A; Merino-Bohórquez V; Martín-Manzanares J; Alonso MM; Maldonado B; Castro L; Belvis M; Benítez B; Caunedo Á; Calleja MÁ; Argüelles-Arias F
    Dig Dis Sci; 2024 Jan; 69(1):228-234. PubMed ID: 37943382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.
    Dorn-Rasmussen M; Buhl S; Brynskov J; Bay JT; Bolstad N; Klausen TW; Warren DJ; Ainsworth MA; Steenholdt C
    Ther Drug Monit; 2022 Apr; 44(2):290-300. PubMed ID: 34387220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients.
    Gil Candel M; Gascón Cánovas JJ; Gómez Espín R; Nicolás de Prado I; Rentero Redondo L; Urbieta Sanz E; Iniesta Navalón C
    Rev Esp Enferm Dig; 2020 Aug; 112(8):590-597. PubMed ID: 32686429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
    Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
    Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease.
    Guiotto C; Daperno M; Frigerio F; Vizzini M; Cerruti R; Ercole E; Cosimato M; Lavagna A; Germano L; Migliardi M; Rocca R
    Dig Liver Dis; 2016 Feb; 48(2):138-43. PubMed ID: 26614644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.